AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21398087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine infusion (0.1, 0.15, or 0.2 mg/kg/h)
Number of subjects: 29
Study 21398087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine (300 mg/day, interquartile range 240-382.5)
Number of subjects: 29
Study 21398087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine
Number of subjects: 29
Study 18608549 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/day soy protein containing 164 mg isoflavones
Number of subjects: 52
Study 16395099 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels > or = 40 mg/dL
Number of subjects: 0
Study 16395099 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels > or = 120 mg/dL
Number of subjects: 0
Study 16395099 — intervention group
Group type: COMPARATOR
Intervention: Chest radiograph-confirmed alveolar consolidation (CXR-AC)
Number of subjects: 0
Study 16395099 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LRTI with CRP levels > or = 40 mg/dL
Number of subjects: 0
Study 16395099 — intervention group
Group type: COMPARATOR
Intervention: C-LRTI alone
Number of subjects: 0
Study 16395099 — intervention group
Group type: COMPARATOR
Intervention: WHO-defined severe pneumonia
Number of subjects: 0
Study 15590251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/kg)
Number of subjects: 22
Study 15590251 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 9226527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (10 mg/kg/day in two doses for 8 weeks)
Number of subjects: 26
Study 9226527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9226527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 26
Study 8434246 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg daily
Number of subjects: 16
Study 8434246 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) 400 mg daily
Number of subjects: 16
Study 2885356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg three times a day)
Number of subjects: 16
Study 2885356 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg and 40 mg)
Number of subjects: 16
Study 2885356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29605122 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized RSA patient protocols
Number of subjects: 40
Study 29605122 — intervention group
Group type: COMPARATOR
Intervention: Standard RSA protocol
Number of subjects: 40
Study 27424292 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT) with external cuing and emotional regulation module
Number of subjects: 70
Study 27424292 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Workshop (control condition)
Number of subjects: 70
Study 24903468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway (NPA) insertion during sedation
Number of subjects: 216
Study 24903468 — intervention group
Group type: COMPARATOR
Intervention: No nasopharyngeal airway (NPA) insertion (control group)
Number of subjects: 216
Study 22435439 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 220 mg twice daily for 90 days
Number of subjects: 44
Study 22435439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20694777 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 32
Study 20694777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 18236303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Condition (interactive, tailored Web‐based intervention)
Number of subjects: 2523
Study 18236303 — intervention group
Group type: COMPARATOR
Intervention: Basic Condition (more linear, text‐based website)
Number of subjects: 2523
Study 16796497 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 37
Study 16796497 — intervention group
Group type: COMPARATOR
Intervention: Traditional home care services
Number of subjects: 37
Study 12665082 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational subtypes
Number of subjects: 252
Study 12665082 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous measure of readiness for change (URICA)
Number of subjects: 252
Study 12665082 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational subtypes and continuous readiness measure
Number of subjects: 252
Study 12665082 — intervention group
Group type: EXPERIMENTAL
Intervention: URICA
Number of subjects: 252
Study 11112236 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (unfractionated heparin or low‐molecular‐weight heparin (reviparin) and a coumarin derivative)
Number of subjects: 1021
Study 9273568 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 42
Study 9273568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 42
Study 9273568 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 42
Study 1350237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.1 mg
Number of subjects: 12
Study 1350237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.2 mg
Number of subjects: 12
Study 1350237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.3 mg
Number of subjects: 12
Study 1350237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 12
Study 1350237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3676230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet L (50 g lactitol/d)
Number of subjects: 8
Study 3676230 — intervention group
Group type: COMPARATOR
Intervention: Diet S (49 g saccharose/d)
Number of subjects: 8
Study 28988345 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 299
Study 28988345 — intervention group
Group type: COMPARATOR
Intervention: Stepwise excavation (SW)
Number of subjects: 299
Study 27567550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose drink (162 kcal)
Number of subjects: 117
Study 27567550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose drink (low-calorie sweetener)
Number of subjects: 117
Study 27567550 — intervention group
Group type: COMPARATOR
Intervention: Water (comparison group)
Number of subjects: 117
Study 24375720 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) cessation
Number of subjects: 0
Study 24375720 — intervention group
Group type: COMPARATOR
Intervention: Sham-OFF
Number of subjects: 0
Study 22460854 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVent‐ASV(®)
Number of subjects: 50
Study 22460854 — intervention group
Group type: COMPARATOR
Intervention: ASV
Number of subjects: 50
Study 20415914 — intervention group
Group type: EXPERIMENTAL
Intervention: Gumtone gel
Number of subjects: 90
Study 20415914 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 90
Study 20415914 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study 18187077 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 89
Study 18187077 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 89
Study 16040409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus petrolatum once daily
Number of subjects: 19
Study 16040409 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 0.005% ointment twice daily
Number of subjects: 19
Study 11791028 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (AT1 antagonist)
Number of subjects: 11
Study 11791028 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 11
Study 10530535 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia/sedation (IVAS)
Number of subjects: 49
Study 10530535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular lidocaine injection (IAL)
Number of subjects: 49
Study 7793542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 42
Study 7793542 — intervention group
Group type: COMPARATOR
Intervention: Room air (Control)
Number of subjects: 42
Study 1913614 — intervention group
Group type: EXPERIMENTAL
Intervention: Curaderm (0.005% BEC)
Number of subjects: 124
Study 1913614 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 124
Study 6763834 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique
Number of subjects: 0
Study 6763834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31618120 — intervention group
Group type: EXPERIMENTAL
Intervention: Logarithmic rule
Number of subjects: 86
Study 31618120 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear rule
Number of subjects: 86
Study 31618120 — intervention group
Group type: COMPARATOR
Intervention: Computer simulations
Number of subjects: 86
Study 26880694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile telehealth (MTH) intervention
Number of subjects: 81
Study 26880694 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study 25671579 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-focused MT (8-hour, 8-week Mindfulness-based Mind Fitness Training)
Number of subjects: 40
Study 25671579 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic-focused MT
Number of subjects: 40
Study 25671579 — intervention group
Group type: COMPARATOR
Intervention: No-training control (NTC)
Number of subjects: 40
Study 25671579 — intervention group
Group type: EXPERIMENTAL
Intervention: Civilian group (CIV)
Number of subjects: 40
Study 24833736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 20
Study 24833736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 21615784 — intervention group
Group type: EXPERIMENTAL
Intervention: Invested with type III stone in monomaxillary PVC flask
Number of subjects: 30
Study 21615784 — intervention group
Group type: COMPARATOR
Intervention: Invested with type III stone in bimaxillary PVC flask
Number of subjects: 30
Study 21615784 — intervention group
Group type: COMPARATOR
Intervention: Invested with laboratory silicone in bimaxillary PVC flask
Number of subjects: 30
Study 18583187 — intervention group
Group type: EXPERIMENTAL
Intervention: Silencer
Number of subjects: 16
Study 18583187 — intervention group
Group type: EXPERIMENTAL
Intervention: Klearway
Number of subjects: 16
Study 18583187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MAA
Number of subjects: 16
Study 17721100 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education skills intervention (n = 431)
Number of subjects: 854
Study 17721100 — intervention group
Group type: COMPARATOR
Intervention: Time-equivalent attention control (n = 423)
Number of subjects: 854
Study 15155349 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL chloroprocaine 1%
Number of subjects: 150
Study 15155349 — intervention group
Group type: COMPARATOR
Intervention: 40 mL chloroprocaine 0.5%
Number of subjects: 150
Study 12370214 — intervention group
Group type: EXPERIMENTAL
Intervention: t10c12 CLA
Number of subjects: 60
Study 12370214 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA mixture
Number of subjects: 60
Study 12370214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9842676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle brace
Number of subjects: 14
Study 9842676 — intervention group
Group type: COMPARATOR
Intervention: No ankle brace (Control)
Number of subjects: 14
Study 8082071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization (5-fluorouracil 750 mg/m2 and recombinant alpha-2a-interferon 9-MU mixed into PVA contrast suspension)
Number of subjects: 24
Study 8082071 — intervention group
Group type: COMPARATOR
Intervention: Embolization (particulate transcatheter polyvinyl alcohol (PVA) 150-250 microns mixed with iodinated radiographic contrast)
Number of subjects: 24
Study 2919760 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg intravenously)
Number of subjects: 40
Study 2919760 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg)
Number of subjects: 40
Study 2919760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-hydroxymidazolam
Number of subjects: 40
Study 1123372 — intervention group
Group type: EXPERIMENTAL
Intervention: Charnley total hip replacement
Number of subjects: 40
Study 1123372 — intervention group
Group type: COMPARATOR
Intervention: Ring total hip prosthesis
Number of subjects: 40
Study 31739784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Intraligamentary Stabilization (DIS)
Number of subjects: 96
Study 31739784 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Brace Ligament Augmentation (IBLA)
Number of subjects: 96
Study 31739784 — intervention group
Group type: COMPARATOR
Intervention: Reconstruction
Number of subjects: 96
Study 31739784 — intervention group
Group type: EXPERIMENTAL
Intervention: DIS or IBLA
Number of subjects: 96
Study 31739784 — intervention group
Group type: COMPARATOR
Intervention: IBLA or Reconstruction
Number of subjects: 96
Study 28072690 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin jet injector (regular insulin and insulin aspart)
Number of subjects: 60
Study 28072690 — intervention group
Group type: COMPARATOR
Intervention: Insulin pen (regular insulin and insulin aspart)
Number of subjects: 60
Study 25879228 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice and olive fruit extract (10.82 mg of monacolins and 9.32 mg of hydroxytyrosol per capsule)
Number of subjects: 50
Study 25879228 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice and olive fruit extract
Number of subjects: 50
Study 25879228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23321763 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of residual gastric volume monitoring
Number of subjects: 449
Study 23321763 — intervention group
Group type: COMPARATOR
Intervention: Routine residual gastric volume monitoring
Number of subjects: 449
Study 20238221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined connective tissue massage, Kabat's technique, kinesitherapy, and home exercise program for 9 weeks (twice a week, 1 hour per session)
Number of subjects: 40
Study 20238221 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program only
Number of subjects: 40
Study 19884713 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with 37% carbamide peroxide (CP37)
Number of subjects: 32
Study 19884713 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching with 10% carbamide peroxide (CP10)
Number of subjects: 32
Study 19884713 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of in-office (CP37) and at-home (CP10) bleaching
Number of subjects: 32
Study 19884713 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 17124431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg daily)
Number of subjects: 150
Study 17124431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statin treatment)
Number of subjects: 150
Study 14691036 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release paclitaxel-eluting stents
Number of subjects: 536
Study 14691036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-release paclitaxel-eluting stents
Number of subjects: 536
Study 14691036 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 536
Study 11578682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) 50 microg/day
Number of subjects: 20
Study 11578682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9695725 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (50, 100, 200, or 400 mg)
Number of subjects: 19
Study 9695725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7988585 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS at 30 mA
Number of subjects: 30
Study 7988585 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal DBS3.3
Number of subjects: 30
Study 7988585 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal DBS3.2
Number of subjects: 30
Study 2656778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 8
Study 29164445 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS® Social Skills Intervention
Number of subjects: 49
Study 28155060 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-loaded DAC® hydrogel coating
Number of subjects: 256
Study 28155060 — intervention group
Group type: COMPARATOR
Intervention: Control group (without coating)
Number of subjects: 256
Study 25162362 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4000 at a dose of 0.7 g/kg (high-dose group)
Number of subjects: 92
Study 25162362 — intervention group
Group type: COMPARATOR
Intervention: PEG 4000 at a dose of 0.3 g/kg (low-dose group)
Number of subjects: 92
Study 24617232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cake-separated moxibustion combined with lifestyle intervention
Number of subjects: 60
Study 24617232 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (control group)
Number of subjects: 60
Study 21262562 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1%
Number of subjects: 50
Study 21262562 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 50
Study 19105428 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 40
Study 19105428 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (control)
Number of subjects: 40
Study 19105428 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Electroacupuncture and Diclofenac sodium
Number of subjects: 40
Study 12684359 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT) and Sibutramine
Number of subjects: 82
Study 12684359 — intervention group
Group type: COMPARATOR
Intervention: Behavior Therapy (BT) and Placebo
Number of subjects: 82
Study 12684359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (after initial treatment)
Number of subjects: 82
Study 12684359 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo to Sibutramine (after switch)
Number of subjects: 82
Study 10194542 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11) administered via 90 min i.v. infusion
Number of subjects: 24
Study 7772472 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrices with elastin
Number of subjects: 7
Study 7772472 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrices with fibronectin
Number of subjects: 7
Study 7772472 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrices with hyaluronic acid
Number of subjects: 7
Study 7772472 — intervention group
Group type: COMPARATOR
Intervention: Control wounds (no collagen matrices)
Number of subjects: 7
Study 2211198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plus para‐aortic irradiation
Number of subjects: 330
Study 2211198 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation only
Number of subjects: 330
Study 376459 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB 365 (clenbuterol) administered at 30 micrograms b.i.d. for 3 days, then reduced to 20 micrograms b.i.d. for an average of 13 days.
Number of subjects: 30
Study 376459 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol administered at 4 mg t.i.d. for an average of 13 days.
Number of subjects: 30
Study 31849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on MRI features
Number of subjects: 138
Study 31849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram incorporating radiomics signature and clinical features
Number of subjects: 138
Study 31849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature in multicenter validation
Number of subjects: 138
Study 31849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature and radiomics nomogram
Number of subjects: 138
Study 31129373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 800
Study 31129373 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging program (Text)
Number of subjects: 800
Study 31129373 — intervention group
Group type: COMPARATOR
Intervention: No Brief Intervention (No BI)
Number of subjects: 800
Study 31129373 — intervention group
Group type: COMPARATOR
Intervention: No Text messaging program (No Text)
Number of subjects: 800
Study 28526625 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training one time per week (M1)
Number of subjects: 88
Study 28526625 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training two times per week (M2)
Number of subjects: 88
Study 28526625 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training three times per week (M3)
Number of subjects: 88
Study 28526625 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group (MCon)
Number of subjects: 88
Study 25179260 — intervention group
Group type: EXPERIMENTAL
Intervention: VCD treatment
Number of subjects: 642
Study 23345050 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ, 13.5 g/day)
Number of subjects: 57
Study 23345050 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (MEPM, 1.5 g/day)
Number of subjects: 57
Study 21132593 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing (TMI)
Number of subjects: 469
Study 21132593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print communication (TPC)
Number of subjects: 469
Study 21132593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (TPC + TMI)
Number of subjects: 469
Study 21132593 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 469
Study 19720383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the supplementary motor area (SMA)
Number of subjects: 0
Study 19720383 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 0
Study 17932841 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day application of topical 0.5% levofloxacin
Number of subjects: 100